AstraZeneca (AZN): A Steady Progressive Dividend Play in Biopharma
Key Takeaways
- AstraZeneca PLC (AZN) offers a current dividend yield of approximately 1.56%, below the pharmaceutical industry average but supported by a progressive policy.
- Annual dividend stands at $3.20 per share, paid semi-annually, with the most recent second interim dividend of $2.17 per share.
- Payout ratio of around 48% indicates strong earnings coverage, enhancing sustainability.
- Dividend growth of 3.23% over the past year aligns with the company's progressive policy aiming for annual maintenance or increases.
- Robust free cash flow of $14.6 billion in operating cash supports ongoing payments amid R&D investments.
- Suitable for long-term investors seeking balanced income and capital appreciation in healthcare.
Understanding AZN's Dividend Approach
AstraZeneca PLC (AZN), a global biopharmaceutical leader, follows a progressive dividend policy designed to maintain or grow payouts annually, reflecting long-term earnings prospects across its investment cycle. The company currently provides an annual dividend of $3.20 per share, yielding about 1.56% based on recent trading levels. Dividends are distributed semi-annually, with a larger second interim payment typically announced alongside full-year results in February and paid in March, and the first interim in September. In my view, this profile positions AZN as a modest dividend stock rather than a high-yield play, prioritizing reinvestment in its innovative pipeline while rewarding shareholders consistently. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Looking at Dividend History and Growth
AstraZeneca has paid dividends semi-annually for decades, with no cuts in recent memory, underscoring payment consistency. The total dividend for fiscal year 2025 rose 3% to $3.20 per share, including a first interim of $1.03 and a second interim of $2.17 (159.5 pence GBP, 19.49 SEK). Recent ex-dividend dates include February 20, 2026 (NYSE), with payment on March 23, 2026. One-year growth stands at 3.23%, supported by the Board's commitment to progression after business investments and credit rating maintenance. Historical trends show steady increases, though not at the pace of dedicated dividend aristocrats, aligning with the biopharma sector's focus on growth. From what I see, this steady progression makes it reliable for those building income over time.
Assessing Dividend Sustainability
The dividend appears highly sustainable, with a payout ratio of approximately 48-49% of earnings, leaving ample room for reinvestment and buffers against volatility. Fiscal 2025 reported EPS of $6.60 covers the $3.20 dividend over 2x. Operating cash flow reached $14.6 billion, dwarfing dividend obligations estimated at around $6.3 billion (based on shares outstanding), while free cash flow generation remains strong despite R&D and capex demands. Net debt stands at $23.4 billion, manageable with an investment-grade rating. Balanced capital allocation—prioritizing R&D, then dividends, and growth opportunities—bolsters long-term viability. One thing that stands out is how this coverage provides a solid foundation even in a capital-intensive industry.
How AZN Stacks Up Against Peers
AstraZeneca's 1.56% yield is modest compared to large-cap pharmaceutical peers. For instance, JNJ offers around 2.1-2.5%, ABBV approximately 3.3%, PFE over 6%, BMY 4.3%, MRK 2.7%, and NVS 3.1%. While lower than high-yield names like PFE or BMY, AZN's profile appeals to investors favoring growth-oriented payouts over maximum current income, given its lower payout ratio and pipeline momentum versus peers with higher yields but elevated payout concerns. This is important because it highlights AZN's balance in a competitive field.
Spotting Opportunities with Tickeron's AI Screener
In my research process, I rely on Tickeron’s AI Screener, an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. It excels at identifying dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. I’ve found it particularly useful for evaluating dividend sustainability across sectors like biopharma. Explore the AI Screener to streamline your research today.
Does AZN Fit Your Dividend Strategy?
AstraZeneca PLC (AZN) suits dividend growth investors and those pursuing total return in the biopharmaceutical space, where modest yields pair with potential capital appreciation from a robust pipeline in oncology, rare diseases, and beyond. Its progressive policy and low payout ratio appeal to conservative long-term holders comfortable with sector volatility tied to drug approvals and patents. Income seekers prioritizing high current yields may look elsewhere, as AZN's 1.56% lags peers, but sustainability metrics and 3% recent growth offer appeal for portfolios balancing yield with expansion. Financial strength, including strong cash flows and investment-grade status, supports resilience, though R&D intensity (a key biopharma trait) could pressure short-term payouts. Overall, it fits diversified strategies for patient investors eyeing healthcare innovation, and I’m watching this closely for its pipeline developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
AZN in upward trend: price expected to rise as it breaks its lower Bollinger Band on September 09, 2026
AZN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 23 of 37 cases where AZN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 62%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 16, 2026. You may want to consider a long position or call options on AZN as a result. In 47 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 60%.
The Moving Average Convergence Divergence (MACD) for AZN just turned positive on September 14, 2026. Looking at past instances where AZN's MACD turned positive, the stock continued to rise in 25 of 41 cases over the following month. The odds of a continued upward trend are 61%.
AZN moved above its 50-day moving average on September 17, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where AZN advanced for three days, in 192 of 337 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 50-day moving average for AZN moved below the 200-day moving average on September 18, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.120) is normal, around the industry mean (19.050). P/E Ratio (24.862) is within average values for comparable stocks, (34.258). Projected Growth (PEG Ratio) (1.190) is also within normal values, averaging (5.614). Dividend Yield (0.019) settles around the average of (0.025) among similar stocks. P/S Ratio (4.148) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 19 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. AZN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement